LRMR Larimar Therapeutics
- 9.510
- +0.370+4.05%
- 9.490
- -0.020-0.21%
Larimar Therapeutics News
Health Care Stocks Climb On Drug News -- Health Care Roundup
Health-care company shares climbed amid positive news for drug makers. The Food and Drug Administration approved Moderna's vaccine to protect against respiratory syncytial virus, a common virus that
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results.SentinelOne reported quarterly losses of 23 cents per share, which
J.P. Morgan Securities: Reiterated the Larimar Therapeutics (LRMR.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $25.00.
J.P. Morgan Securities: Reiterated the Larimar Therapeutics (LRMR.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $25.00 to $25.00.
Larimar Therapeutics Shares Rise 15% Nomlabofusp Selected for FDA Program
By Chris Wack Larimar Therapeutics shares were up 15% at $8.17 after the company said the Food and Drug Administration has selected nomlabofusp to participate in the Support for Clinical Trials Advan
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday.Shares of Ambarella, Inc. (NASDAQ:AMBA) rose sharply during Friday's session following strong first-quarter earnings and u
Express News | Larimar Therapeutics Inc: Selected by FDA to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseasesNomlabofusp was selected based on potential for clinical benefit in
Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 0.5% on Tuesday.Shares of Hello Group Inc. (NASDAQ:MOMO) fell sharply in today's pre-market trading following
Citi Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Raises Target Price to $14
Citi analyst Samantha Semenkow maintains $Larimar Therapeutics(LRMR.US)$ with a buy rating, and adjusts the target price from $10 to $14.According to TipRanks data, the analyst has a success rate of 4
Larimar Therapeutics Is Maintained at Buy by Citigroup
Larimar Therapeutics Is Maintained at Buy by Citigroup
Citi: Maintaining the Larimar Therapeutics (LRMR.US) rating, adjusted from buy to buy rating, and adjusted the target price from $10.00 to $14.00.
Citi: Maintaining the Larimar Therapeutics (LRMR.US) rating, adjusted from buy to buy rating, and adjusted the target price from $10.00 to $14.00.
Citigroup Maintains Buy on Larimar Therapeutics, Raises Price Target to $14
Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and raises the price target from $10 to $14.
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug
On Monday, Larimar Therapeutics Inc (NASDAQ:LRMR) announced that the FDA removed the previous partial clinical hold on -nomlabofusp (CTI-1601) clinical program for Friedreich's Ataxia (FA). Nomlabofus
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of James Hardie Industries plc (NYSE:JHX) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financial results.James Hardie Industries posted adjuste
J.P. Morgan Securities: The Larimar Therapeutics (LRMR.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $25.00.
J.P. Morgan Securities: The Larimar Therapeutics (LRMR.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $25.00.
JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target
JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintains $25 price target.
Larimar Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 194.81% JMP Securities → $25 Reiterates Market Outperform → Market Outperform 04/03/2024 194.81
XPeng Posts Strong Results, Joins Larimar Therapeutics, Transcat And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 50 points on Tuesday.Shares of XPeng Inc. (NYSE:XPEV) rose sharply during Tuesday's session after the company reported better-th
Sector Update: Health Care Stocks Steady Premarket Tuesday
Health care stocks were steady premarket Tuesday, with the the Health Care Select Sector SPDR Fund (XLV) was down a slight 0.1% and the iShares Biotechnology ETF (IBB) recently unchanged. Larimar Ther
Investors Tread Cautiously as Nvidia Earnings Loom, Driving Muted Premarket Action for US Equity Futures
US equity futures were mostly flat premarket Tuesday as traders turned cautious ahead of quarterly earnings from chipmaker Nvidia (NVDA) due for release later in the week. Dow Jones Industrial Average
Analysis
Price Target
No Data
